---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-22-002286"
form_type: "8-K"
ticker: "LEXX"
cik: "0001348362"
company_name: "Lexaria Bioscience Corp."
filed_at: "2022-10-28T23:59:59+00:00"
generated_at: "2026-06-22T22:29:22.937052+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Lexaria's DehydraTECH-CBD lowers blood pressure in 66-patient hypertension study

## Summary
- Systolic BP reduced up to 5.60 mmHg (p<0.001) over 5 weeks vs. placebo; no serious adverse events.
- BP reduction sustained for full study duration, exceeding cardiovascular risk reduction thresholds (4.6/2.2 mmHg).
- Additive BP lowering observed in patients already on standard antihypertensive therapy.
- Study used 225-450 mg/day DehydraTECH-CBD with zero serious adverse events and no liver enzyme changes.
- Results support planned Phase Ib IND study with FDA; full results to be submitted for peer review.

## SEC filing metadata
- accession: 0001640334-22-002286
- form_type: 8-K
- ticker: LEXX
- cik: 0001348362
- company_name: Lexaria Bioscience Corp.
- filed_at: 2022-10-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1348362/000164033422002286/0001640334-22-002286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1348362/000164033422002286/lxrp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-22-002286
- JSON: https://secwatch.observer/filing/0001640334-22-002286.json
- Plain text: https://secwatch.observer/filing/0001640334-22-002286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.